ReShape Lifesciences

RSLS72

High Growth

$5.24arrow_drop_up1.35%$0.07

High Growth

RSLS72

$5.24

arrow_drop_up1.35%$0.07

High Growth

Performance History

Key Stats
Open	$4.90
Prev. Close	$5.17
EPS	24.10
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$2.65M

	LOW	HIGH
Day Range	4.81	5.37
52 Week Range	4.22	34.22

Ratios

Revenue	-





EPS	24.10

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ReShape Lifesciences (RSLS)

ReShape Lifesciences Inc. (RSLS) is a leading medical device company that focuses on the development, manufacturing, and commercialization of minimally invasive medical devices to treat obesity and metabolic diseases. The company's flagship product is the ReShape Integrated Dual Balloon (IDB) System, which is designed to help obese patients achieve significant weight loss. The ReShape IDB System is a non-surgical weight loss solution that is inserted into the patient's stomach through an endoscopic procedure. The system consists of two connected balloons that are filled with saline, creating a feeling of fullness and reducing the patient's appetite. The ReShape IDB System has been clinically proven to help patients lose weight and improve their overall health.

With an impressive track record of innovation and success, ReShape Lifesciences Inc. has established itself as a leader in the field of minimally invasive weight loss solutions. The company's commitment to research and development has resulted in the development of innovative products that address the needs of patients suffering from obesity and related conditions. In addition to its flagship product, the ReShape IDB System, ReShape Lifesciences Inc. also offers a range of other medical devices and accessories that support weight loss and improve patient outcomes. The company's products are used by healthcare professionals around the world to help patients regain their health and quality of life.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Mr. Paul F. Hickey
Headquarters: San Clemente
Employees: 40
Exchange: NASDAQ

Keep an eye on ReShape Lifesciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ReShape Lifesciences's (RSLS) price per share?

The current price per share for ReShape Lifesciences (RSLS) is $5.24. The stock has seen a price change of $0.07 recently, indicating a 1.35% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ReShape Lifesciences (RSLS)?

For ReShape Lifesciences (RSLS), the 52-week high is $34.22, which is 553.05% from the current price. The 52-week low is $4.23, the current price is 23.99% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ReShape Lifesciences (RSLS) a growth stock?

ReShape Lifesciences (RSLS) has shown an average price growth of -6.65% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ReShape Lifesciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ReShape Lifesciences (RSLS) stock price performance year to date (YTD)?

As of the latest data, ReShape Lifesciences (RSLS) has a year-to-date price change of -66.14%. Over the past month, the stock has experienced a price change of -5.76%. Over the last three months, the change has been -45.54%. Over the past six months, the figure is -48.73%.

help

Is ReShape Lifesciences (RSLS) a profitable company?

ReShape Lifesciences (RSLS) has a net income of -$11.39M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 63.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -104.53% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $5.55M. Operating income is noted at -$14.64M. Furthermore, the EBITDA is -$9.19M.

help

What is the market capitalization of ReShape Lifesciences (RSLS)?

ReShape Lifesciences (RSLS) has a market capitalization of $2.65M. The average daily trading volume is 5.15, indicating the stock's liquidity and investor engagement.